ObjectivesWe sought to determine whether the addition of spironolactone to angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs) improves left ventricular mass and arterial stiffness in early-stage chronic kidney disease (CKD).BackgroundChronic kidney disease is associated with a high risk of cardiovascular disease and a high prevalence of left ventricular hypertrophy and arterial stiffness that confer an adverse prognosis. It is believed that these abnormalities are in part a result of activation of the renin-angiotensin-aldosterone system.MethodsAfter an active run-in phase with spironolactone 25 mg once daily, 112 patients with stage 2 and 3 CKD with good blood pressure control (mean daytime ambulatory b...
BACKGROUND AND OBJECTIVES: In a randomized double-blind, placebo-controlled trial, treatment with sp...
BACKGROUNDS: We investigated the relationship between spironolactone use and all-cause mortality in ...
Background: Spironolactone treatment reduces mortality in haemodialysis (HD) patients. The objective...
ObjectivesWe sought to determine whether the addition of spironolactone to angiotensin-converting en...
This thesis examined whether patients with early stage chronic kidney disease (CKD) have abnormaliti...
BACKGROUND AND OBJECTIVES In a randomized double-blind, placebo-controlled trial, treatment with ...
Background Chronic kidney disease (CKD) is associated with increased left ventricular (LV) mass and ...
Background: Chronic kidney disease is associated with increased arterial stiffness even in the earl...
BACKGROUND: Chronic kidney disease is associated with increased arterial stiffness even in the early...
Background: The role of spironolactone treatment in hemodialysis patients is debated, but a survival...
We performed this study to assess whether low dose spironolactone could be admi-nistered in hemodial...
International audienceOBJECTIVES: Hemodialysis patients have a cardiovascular mortality rate of 20-4...
Background: Spironolactone, a non-selective mineralocorticoid receptor antagonist, can protect again...
Objectives To determine whether low-dose spironolactone can safely lower arterial stiffness in patie...
ObjectivesThis study sought to assess whether spironolactone treatment reduces the high incidence of...
BACKGROUND AND OBJECTIVES: In a randomized double-blind, placebo-controlled trial, treatment with sp...
BACKGROUNDS: We investigated the relationship between spironolactone use and all-cause mortality in ...
Background: Spironolactone treatment reduces mortality in haemodialysis (HD) patients. The objective...
ObjectivesWe sought to determine whether the addition of spironolactone to angiotensin-converting en...
This thesis examined whether patients with early stage chronic kidney disease (CKD) have abnormaliti...
BACKGROUND AND OBJECTIVES In a randomized double-blind, placebo-controlled trial, treatment with ...
Background Chronic kidney disease (CKD) is associated with increased left ventricular (LV) mass and ...
Background: Chronic kidney disease is associated with increased arterial stiffness even in the earl...
BACKGROUND: Chronic kidney disease is associated with increased arterial stiffness even in the early...
Background: The role of spironolactone treatment in hemodialysis patients is debated, but a survival...
We performed this study to assess whether low dose spironolactone could be admi-nistered in hemodial...
International audienceOBJECTIVES: Hemodialysis patients have a cardiovascular mortality rate of 20-4...
Background: Spironolactone, a non-selective mineralocorticoid receptor antagonist, can protect again...
Objectives To determine whether low-dose spironolactone can safely lower arterial stiffness in patie...
ObjectivesThis study sought to assess whether spironolactone treatment reduces the high incidence of...
BACKGROUND AND OBJECTIVES: In a randomized double-blind, placebo-controlled trial, treatment with sp...
BACKGROUNDS: We investigated the relationship between spironolactone use and all-cause mortality in ...
Background: Spironolactone treatment reduces mortality in haemodialysis (HD) patients. The objective...